Insulet Successfully Defends Its Intellectual Property Against EOFlow Co. in U.S. District Court
Insulet Successfully Defends Its Intellectual Property Against EOFlow Co. in U.S. District Court
The jury found that EOFlow and several other defendants misappropriated Insulet's trade secrets. The jury awarded the Company $170 million in compensatory damages from EOFlow and an additional $282 million in exemplary damages from EOFlow for willful and malicious misappropriation, for a total damages award of $452 million. EOFlow's ability to satisfy this damage award is not known with certainty.Jury awards $452M in damages
陪審團裁定賠償金額爲45200萬美元
ACTON, Mass.--(BUSINESS WIRE)--Insulet Corporation (NASDAQ: PODD) (Insulet or the Company), the global leader in tubeless insulin pump technology with its Omnipod brand of products, announced that it has successfully defended its intellectual property against EOFlow Co., Ltd. ("EOFlow") in federal court.
馬薩諸塞州阿克頓——（商業資訊）——銀休特公司（納斯達克：PODD）（銀休特或該公司），全球無管道胰島素泵技術的領導者，旗下擁有Omnipod品牌產品，宣佈其在聯邦法庭成功維護了其知識產權，針對EOFlow有限公司（「EOFlow」）的訴訟
After a four-week trial in the U.S. District Court for the District of Massachusetts in the matter of Insulet Corporation vs. EOFlow et al., a jury verdict was returned in favor of Insulet on December 3, 2024.
在美國馬薩諸塞州地區法院，銀休特公司訴EOFlow等案的爲期四周的審判後，陪審團於2024年12月3日作出了有利於銀休特的裁決。
The jury found that EOFlow and several other defendants misappropriated Insulet's trade secrets. The jury awarded the Company $170 million in compensatory damages from EOFlow and an additional $282 million in exemplary damages from EOFlow for willful and malicious misappropriation, for a total damages award of $452 million. EOFlow's ability to satisfy this damage award is not known with certainty.
陪審團發現EOFlow和其他幾名被告盜用了銀休特的商業祕密。陪審團判決EOFlow賠償銀休特公司17000萬美元的補償性損害賠償，以及額外的28200萬美元的懲罰性損害賠償，總賠償金額爲45200萬美元。目前尚不清楚EOFlow是否能夠滿足這一賠償要求。
"We are extremely pleased with the jury's verdict, which validates our commitment to protecting our technology and defending our intellectual property against misappropriation and infringement," said Jim Hollingshead, Insulet President and Chief Executive Officer. "We will not only enforce our patents, but also zealously protect our valuable trade secrets, in which we've invested heavily to improve the lives of people with diabetes."
「我們對陪審團的裁決感到非常高興，這驗證了我們保護技術和防止知識產權被盜用及侵權的承諾，」銀休特總裁兼首席執行官Jim Hollingshead表示。「我們不僅會執行我們的專利，還將積極保護我們的寶貴商業祕密。我們在這些商業祕密上投入了大量資金，以改善糖尿病患者的生活。」
About Insulet Corporation:
關於Insulet公司:
Insulet Corporation (NASDAQ: PODD), headquartered in Massachusetts, is an innovative medical device company dedicated to simplifying life for people with diabetes and other conditions through its Omnipod product platform. The Omnipod Insulin Management System provides a unique alternative to traditional insulin delivery methods. With its simple, wearable design, the tubeless disposable Pod provides up to three days of non-stop insulin delivery, without the need to see or handle a needle. Insulet's flagship innovation, the Omnipod 5 Automated Insulin Delivery System, integrates with a continuous glucose monitor to manage blood sugar with no multiple daily injections, zero fingersticks, and can be controlled by a compatible personal smartphone in the U.S. or by the Omnipod 5 Controller. Insulet also leverages the unique design of its Pod by tailoring its Omnipod technology platform for the delivery of non-insulin subcutaneous drugs across other therapeutic areas. For more information, please visit insulet.com and omnipod.com.
銀休特公司（納斯達克：PODD）總部位於馬薩諸塞州，是一家創新的醫療器械公司，致力於通過其Omnipod產品平台簡化糖尿病和其他疾病患者的生活。Omnipod胰島素管理系統爲傳統胰島素傳輸方法提供了獨特的替代方案。憑藉其簡單、可穿戴的設計，該無管道一次性Pod提供長達三天的不間斷胰島素傳輸，無需看或觸摸針頭。銀休特的旗艦創新——Omnipod 5自動胰島素傳輸系統與連續血糖監測器集成，以管理血糖，無需多次每日注射，無需指尖抽血，並且可以通過兼容的個人智能手機在美國控制，或者通過Omnipod 5人形機器人-電機控制器控制。銀休特還利用其Pod的獨特設計，將其Omnipod技術平台定製用於傳遞其他治療領域的非胰島素皮下注射藥物。欲了解更多信息，請訪問insulet.com和omnipod.com。
2024 Insulet Corporation. Omnipod is a registered trademark of Insulet Corporation. All rights reserved. All other trademarks are the property of their respective owners.
2024 銀休特公司。Omnipod是銀休特公司的註冊商標。所有權利保留。其他商標均爲各自所有者的財產。
View source version on businesswire.com:
在businesswire.com查看源版本：
Investor Relations:
June Lazaroff
Senior Director, Investor Relations
(978) 600-7718
jlazaroff@insulet.com
Media:
Angela Geryak Wiczek
Senior Director, Corporate Communications
(978) 932-0611
awiczek@insulet.com
投資者關係：
六月·拉扎羅夫
高級董事，投資者關係
(978) 600-7718
jlazaroff@insulet.com
媒體：
安吉拉·格列亞克·維切克
高級董事，企業通信
(978) 932-0611
awiczek@insulet.com
Source: Insulet Corporation
來源：銀休特公司
譯文內容由第三人軟體翻譯。